{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:22:45Z","timestamp":1761016965828,"version":"3.40.3"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology"],"published-print":{"date-parts":[[2001,7,24]]},"DOI":"10.1212\/wnl.57.2.196","type":"journal-article","created":{"date-parts":[[2012,5,14]],"date-time":"2012-05-14T23:40:21Z","timestamp":1337038821000},"page":"196-200","source":"Crossref","is-referenced-by-count":51,"title":["Visual field constriction"],"prefix":"10.1212","volume":"57","author":[{"given":"G. J.","family":"Sills","sequence":"first","affiliation":[{"name":"From the Epilepsy Unit, University Department of Medicine and Therapeutics (Drs. Sills, Butler, Forrest, and Brodie), Western Infirmary, Glasgow, Scotland; and Pharmacology and Therapeutics Unit, University Department of Clinical Neurology (Drs. Patsalos and Ratnaraj), Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.N.","family":"Patsalos","sequence":"additional","affiliation":[{"name":"From the Epilepsy Unit, University Department of Medicine and Therapeutics (Drs. Sills, Butler, Forrest, and Brodie), Western Infirmary, Glasgow, Scotland; and Pharmacology and Therapeutics Unit, University Department of Clinical Neurology (Drs. Patsalos and Ratnaraj), Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Butler","sequence":"additional","affiliation":[{"name":"From the Epilepsy Unit, University Department of Medicine and Therapeutics (Drs. Sills, Butler, Forrest, and Brodie), Western Infirmary, Glasgow, Scotland; and Pharmacology and Therapeutics Unit, University Department of Clinical Neurology (Drs. Patsalos and Ratnaraj), Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Forrest","sequence":"additional","affiliation":[{"name":"From the Epilepsy Unit, University Department of Medicine and Therapeutics (Drs. Sills, Butler, Forrest, and Brodie), Western Infirmary, Glasgow, Scotland; and Pharmacology and Therapeutics Unit, University Department of Clinical Neurology (Drs. Patsalos and Ratnaraj), Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Ratnaraj","sequence":"additional","affiliation":[{"name":"From the Epilepsy Unit, University Department of Medicine and Therapeutics (Drs. Sills, Butler, Forrest, and Brodie), Western Infirmary, Glasgow, Scotland; and Pharmacology and Therapeutics Unit, University Department of Clinical Neurology (Drs. Patsalos and Ratnaraj), Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Brodie","sequence":"additional","affiliation":[{"name":"From the Epilepsy Unit, University Department of Medicine and Therapeutics (Drs. Sills, Butler, Forrest, and Brodie), Western Infirmary, Glasgow, Scotland; and Pharmacology and Therapeutics Unit, University Department of Clinical Neurology (Drs. Patsalos and Ratnaraj), Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Editorial. Vigabatrin. Lancet 1989;i:532\u2013533.","DOI":"10.1016\/S0140-6736(89)90072-X"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199606133342407"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.18376"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb02049.x"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/088307380001500304"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.314.7075.180"},{"key":"e_1_3_2_8_2","first-page":"1693","volume":"314","year":"1997","unstructured":"Wilson EA, Brodie MJ, Wong IC, et al. Severe persistent visual field constriction associated with vigabatrin. BMJ . 1997; 314: 1693\u20131695.","journal-title":"BMJ"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7126.232"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.5.922"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(200007)48:1<60::AID-ANA9>3.0.CO;2-E"},{"key":"e_1_3_2_12_2","first-page":"40","volume":"55","year":"2000","unstructured":"Johnson MA, Krauss GL, Miller NR, Medura M, Paul SR. Visual function loss from vigabatrin. Effect of stopping the drug. Neurology . 2000; 55: 40\u201345.","journal-title":"Neurology"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.3.614"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.67.6.716"},{"key":"e_1_3_2_15_2","unstructured":"Jung MJ Palfreyman MG. Vigabatrin: Mechanisms of action. In: Levy RH Mattson RH Meldrum BS eds. Antiepileptic drugs 4th ed. New York: Raven Press 1995: 903\u2013913."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410250302"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410350216"},{"key":"e_1_3_2_18_2","first-page":"167","volume":"23","year":"1997","unstructured":"White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res . 1997; 23: 167\u2013179.","journal-title":"Epilepsy Res"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00084-3"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1995.tb02576.x"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.3.473"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00227.x"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)05035-6"},{"key":"e_1_3_2_24_2","first-page":"6.","volume":"39","year":"1998","unstructured":"Beran RG, Currie J, Sandbach J, Plunkett M. Visual field restriction with new antiepileptic medication. Epilepsia . 1998; 39 (suppl 2): 6.Abstract.","journal-title":"Epilepsia"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.3.333"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)00105-2"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199808000-00013"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(92)80045-R"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1966.tb09873.x"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(08)63609-2"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0022-3565(25)24999-0","volume":"238","year":"1986","unstructured":"Cubells JF, Blanchard JS, Smith DM, Makman MH. In vivo action of enzyme-activated irreversible inhibitors of glutamic acid decarboxylase and gamma-aminobutyric acid transaminase in retina vs. brain. J Pharmacol Exp Ther . 1986; 238: 508\u2013514.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1990.tb15803.x"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.1999.0326"},{"key":"e_1_3_2_34_2","first-page":"1778.","volume":"51","year":"1998","unstructured":"Beck RW, Brigell MG, Roubertie A, et al. Vigabatrin-associated retinal cone system dysfunction. Neurology . 1998; 51: 1778.","journal-title":"Neurology"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/019262338701500203"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/019262339001800201"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/019262339302100507"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00134.x"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)90345-7"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0922-4106(94)90089-2"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)79254-0"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200020060-00001"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1002416918247"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.57.2.196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T01:23:04Z","timestamp":1743124984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.57.2.196"}},"subtitle":["Accumulation of vigabatrin but not tiagabine in the retina"],"short-title":[],"issued":{"date-parts":[[2001,7,24]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,7,24]]}},"alternative-id":["10.1212\/WNL.57.2.196"],"URL":"https:\/\/doi.org\/10.1212\/wnl.57.2.196","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"type":"print","value":"0028-3878"},{"type":"electronic","value":"1526-632X"}],"subject":[],"published":{"date-parts":[[2001,7,24]]}}}